Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.56 |
| ▸ | BCHE | P06276 | 2/20 | 0.55 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | EPOR | P19235 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 4-Hydroxyacetophenone SCHEMBL334308 | 0.87 | MAOB (0.56) | ALOX5BCHEMAOBL3MBTL1SMN1; SMN2 | |
| SCHEMBL334377 | 0.83 | NQO1 (0.44) | SMN1; SMN2 | |
| SCHEMBL335260 | 0.81 | HRH1 (0.45) | ALOX5 | |
| SCHEMBL334955 | 0.81 | TRPM8 (0.52) | GAARAB9ASMN1; SMN2 | |
| SCHEMBL334872 | 0.79 | MAPT (0.45) | BCHEL3MBTL1GAAMAPT | |
| SCHEMBL10243525 | 0.79 | ALOX5 (0.54) | ALOX5BCHEL3MBTL1MAPTRAB9A | |
| SCHEMBL334241 | 0.79 | ALOX5 (0.43) | ALOX5MAOBMAOA | |
| SCHEMBL10875504 | 0.77 | ALOX5 (0.57) | ALOX5BCHEMAOBL3MBTL1GAA | |
| SCHEMBL10877817 | 0.77 | ALOX5 (0.57) | ALOX5BCHEMAOBL3MBTL1GAA | |
| SCHEMBL335079 | 0.75 | TAAR1 (0.42) | ALOX5BCHEL3MBTL1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1985620-A1 | 10a-AZALIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | ALOX5 2387/4885BCHE 1393/4885MAOB 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.